SALSA MLPA P028 FHL probemix - 50 reactions

application: Uveal melanoma
region: 1p, chr.3, 6p, 8q Detailní informace

Cena s DPH € 573.54
Cena bez DPH € 474.00
 50 react
Dostupnost Skladem
Kód produktu P028-050R

Nejnovější informace o produktu naleznete exklusivně na stránkách výrobce MRC-Holland www.mlpa.com (nové okno)

Detailní popis SALSA MLPA P028 FHL probemix - 50 reactions

P027-050R SALSA MLPA P027 Uveal melanoma probemix – 50 rxn

Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, with mortality over 50% usually due to metastatic spread to the liver. Recent research suggests that UMs with monosomy 3 (50-60% of all uveal melanomas) represent a distinct pathological entity as compared to those with normal disomy 3, as monosomy 3 strongly correlates with metastatic death. Chromosome 6 aberrations probably constitute a second entry point in the process of carcinogenesis, while gains in 8q seem to appear later in the natural history of UMs due to their higher frequency in larger tumours. Early detection of high risk UM patients would enable better screening for metastasis and for optimized therapy selection, and as well to reassure patients with no loss of chromosome 3, which is associated with very good prognosis.

This P027-C1 Uveal melanoma MLPA probemix contains several probes on chromosomes 1p, 3, 6 and 8 (MYC region). In addition, it contains 12 reference probes detecting sequences in autosomal chromosome regions that are relatively stable in UM.

This SALSA® MLPA® probemix is designed to detect deletions/duplications of one or more sequences in the above mentioned chromosomal regions in a DNA sample. Heterozygous deletions of probe recognition sequences should give a 35-50% reduced relative peak height of the amplification product of that probe. Note that a mutation or polymorphism in the sequence detected by a probe can also cause a  reduction in relative peak height, even when not located exactly on the ligation site! In addition, some probe signals are more sensitive to sample purity and small changes in experimental conditions. Therefore, deletions and duplications detected by MLPA should always be confirmed by other methods. Not all deletions and duplications detected by MLPA will be pathogenic; users should always verify the latest scientific literature when interpreting their findings.

Kontaktujte nás

BIOGEN PRAHA s.r.o.
Ke sv. Izidoru 2293/4A
140 00 PRAHA 4

Tel.: +420 241 401 693
Fax: +420 241 401 694
E-mail: biogen@biogen.cz

Novinky na e-mail